Background: The purpose of this study is to clarify the prognostic value of lymphovascular invasion (LVI) in patients with surgically resected T1-3N0 non-small cell lung cancer (NSCLC) according to the eighth edition of the TNM Classification of the American Joint Committee on Cancer (AJCC). Method: A total of 442 NSCLC patients who received curative surgery and were confirmed with pathologic T1-3N0 between March 2000 and August 2015 were reviewed. The pathological stages were re-evaluated according to the eighth edition of the TNM Classification of the AJCC. Result: The 5-year recurrence-free survival (RFS) rate for total cohort was 69.7%, and the 5-year overall survival (OS) rate was 78.0%. LVI was present in 89 patients (19.9%). The presence of LVI decreased the 5-year RFS rate significantly (47.5% vs. 72.3%, p < 0.001) and the 5-year OS rate (62.5% vs. 81.1%, p < 0.001). The differences between LVI group and non-LVI group were more remarkable in T2a-bN0 staged patients compared with T1a-c staged patients (T1a-c patients: 63.6% vs. 78.0%, p ¼ 0.004; T2a-b patients: 31.7% vs. 64.9%, p ¼ 0.027, respectively). Multivariate analysis revealed that the presence of LVI was a significant predictor for RFS (p < 0.001) but an insignificant factor for OS. In T2a-bN0 staged patients, the 5year OS rate was significantly lower in patients with LVI than in patients without LVI (50.0% vs. 74.4%, p ¼ 0.045), whereas T1a-c staged patients did not show a significant difference in 5-year OS according to the presence of LVI (p ¼ 0.196). Conclusion: LVI is a significant associated factor for RFS in patients with stage T1-3N0 NSCLC. Prognostic impact of LVI is more remarkable in patients with more than T2N0 stage compared to patients with the T1N0 disease. Keywords: non small cell lung cancer, lymphovascular invasion, patterns of recurrence Background: A number of genes have been reported as aberrantly methylated in lung tumors. Here, we investigate the relationship between gene methylation in lung tumors relative to matching normal lung tissue, and whether DNA methylation changes can be detected in paired blood samples. Method: Primary tumor samples (n¼65), corresponding nonmalignant lung tissues (n¼65) and maching blood samples (n¼51) were obtained from NSCLC patients undergoing curative resectional surgery. Using bisulfite pyrosequencing, CpG methylation was quantified at seven genes (RASSF1A, CDH13, MGMT, ESR1, HOXA9, SOX1 and DAPK) in lung tumor, matching pathologically normal lung tissue, and circulating blood samples. We wanted to determine whether these methylation changes are specific to lung tumors, and test whether these changes are detectable in patients' blood samples. We also analyzed possible associations between DNA methylation and clinicopathologic features. Result: We observed that genes SOX1, RASSF1A, HOXA9, CDH13 and DAPK were significantly hypermethylated in lung tumors compared to match normal tissue. However, these changes could not be detected in patients' blood samples, indicating a low feasibility of detecting lung cancer by analyzing these genes in a blood-based test. We confirmed that hypermethylation of SOX1, RASSF1A, HOXA9, CDH13 and DAPK play a role in NSCLC pathogenesis, but also showed that these genes are not suitable markers for early detection of NSCLC. Lastly, we found that histology and gender were associated with methylation at the CDH13 gene, while stage was associated with methylation at MGMT. Conclusion: Our results show higher methylation of SOX1, RASSF1A, HOXA9, CDH13 and DAPK genes in lung tumors compared to matching normal lung tissue. The lack of reflection of these methylation changes in blood samples from patients with NSCLC indicates their poor suitability for a screening test. (NSCLC) , and in 30% of diagnosed patients, recurrence will develop within 5 years. Optimal postoperative adjuvant therapy is still ambiguous for stage I NSCLC. Here, we aimed to develop and validate a feasible tool for recurrent risk assessment of stage I NSCLC. Method: This retrospective study incorporated the gene expression profiles from 14 public NSCLC cohorts, including 13 microarray data sets and 1 RNA-Seq data set for The Cancer Genome Atlas (TCGA) lung adenocarcinoma cohort. In discovery phase, multiple eligible microarray data sets were used to select statistically significant genes thought to be predictive by two algorithms, Least Absolute Shrinkage and Selector Operation and Support Vector Machine-Recursive Feature Elimination. In the training phase, candidate genes were used to generate a recurrence related signature in TCGA cohort by penalized Cox regression.
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